Resalis Therapeutics, a biotechnology company pioneering microRNA-targeted therapies, today announced the appointment ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Orbital Therapeutics, a company focused on enhancing global health by unleashing the full potential of RNA medicines to treat human disease, today announced the ...

Funds to advance clinical development of heart failure lead candidate and expand platform targeting the regulatory genome HAYA Therapeutics, SA, a biotechnology company pioneering precision RNA-guided ...

Using RNA to interfere with a gene’s expression of disease-causing proteins is a validated therapeutic approach, but so far, the products in this drug class only address liver proteins. Reducing ...

Collaboration will harness the potential of non coding RNAs (ncRNAs) in regenerating heart tissue Ethris will contribute its proprietary SNaP LNP platform for precise ncRNA delivery while Heqet ...

Lexeo Therapeutics partners for $40 million investment to develop RNA-based therapies for genetic cardiac diseases using non-viral delivery technology. Lexeo Therapeutics, Inc. announced a strategic ...

NMU-Symphony™ is the next generation of the Nutcracker ® Manufacturing Unit, optimized for RNA-based individualized manufacturing of therapeutics The company has successfully completed manufacturing ...

The investment will expand RNA Technologies & Therapeutics’ operations and allow partners of both companies to leverage combined expertise in RNA-LNP therapeutics VANCOUVER, British Columbia, January ...

With the question of immunotherapeutics’ efficacy answered in the resounding affirmative, the challenge has shifted to the practical considerations of how to cost-effectively manufacture these highly ...